FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:2551-2553 December 25, 2003 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Attal, M. PubMed Citation

Contrary to a widely held belief, multiple myeloma is not a rare, rapidly fatal disorder that affects only elderly patients. Instead, it is the second most common hematologic cancer after non-Hodgkin's lymphoma — more than 50,000 patients in the United States alone have the disease. About half of these patients received the diagnosis when they were younger than 60 years of age, and increasingly, the disease is detected in persons under the age of 40. The detection of myeloma in patients who are relatively young and otherwise healthy has allowed the use of increasingly aggressive and potentially more efficacious therapies.

. . . [Full Text of this Article]

Source Information

From the Bone Marrow and Stem Cell Transplant Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia.

This article has been cited by other articles:

• San-Miguel, J., Harousseau, J.-L., Joshua, D., Anderson, K. C. (2008). Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents. JCO 26: 2761-2766 [Abstract] [Full Text]  
• Murashige, N., Kishi, Y., Chng, W. J., Musto, P., Attal, M. (2004). Tandem Bone Marrow Transplantation in Multiple Myeloma. NEJM 350: 1466-1467 [Full Text]